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Abstract
Muscle invasive bladder cancer (MIBC, stageT2) is generally associated with poor prog-
nosis, constituting the second most common cause of death among genitourinary tumours.
Due to high molecular heterogeneity significant variations in the natural history and disease
outcome have been observed. This has also delayed the introduction of personalized thera-
peutics, making advanced stage bladder cancer almost an orphan disease in terms of treat-
ment. Altered protein glycosylation translated by the expression of the sialyl-Tn antigen
(STn) and its precursor Tn as well as the activation of the PI3K/Akt/mTOR pathway are can-
cer-associated events that may hold potential for patient stratification and guided therapy.
Therefore, a retrospective design, 96 bladder tumours of different stages (Ta, T1-T4) was
screened for STn and phosphorylated forms of Akt (pAkt), mTOR (pmTOR), S6 (pS6) and
PTEN, related with the activation of the PI3K/Akt/mTOR pathway. In our series the expres-
sion of Tn was residual and was not linked to stage or outcome, while STn was statically
higher in MIBC when compared to non-muscle invasive tumours (p = 0.001) and associated
decreased cancer-specific survival (log rank p = 0.024). Conversely, PI3K/Akt/mTOR path-
way intermediates showed an equal distribution between non-muscle invasive bladder can-
cer (NMIBC) and MIBC and did not associate with cancer-specif survival (CSS) in any of
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these groups. However, the overexpression of pAKT, pmTOR and/or pS6 allowed discrimi-
nating STn-positive advanced stage bladder tumours facing worst CSS (p = 0.027). Further-
more, multivariate Cox regression analysis revealed that overexpression of PI3K/Akt/
mTOR pathway proteins in STn+ MIBC was independently associated with approximately
6-fold risk of death by cancer (p = 0.039). Mice bearing advanced stage chemically-induced
bladder tumours mimicking the histological and molecular nature of human tumours were
then administrated with mTOR-pathway inhibitor sirolimus (rapamycin). This decreased the
number of invasive lesions and, concomitantly, the expression of STn and also pS6, the
downstream effector of the PI3K/Akt/mTOR pathway. In conclusion, STn was found to be
marker of poor prognosis in bladder cancer and, in combination with PI3K/Akt/mTOR path-
way evaluation, holds potential to improve the stratification of stage disease. Animal experi-
ments suggest that mTOR pathway inhibition could be a potential therapeutic approach for
this specific subtype of MIBC.
Introduction
Bladder cancer is the second most deadly genitourinary tumour and presents significantly
worse prognosis uponmuscularis propria invasion [1]. Approximately 20–30% of the newly
diagnosed cases are muscle invasive bladder cancers (MIBC; T2-T4 stages), while 50% are non-
muscle invasive bladder tumours (NMIBC) with high potential to progress to invasion. MIBC
treatment includes cystectomy and (neo)adjuvant cisplatin-based chemotherapy regimens [2].
However, significant variations in the natural history of the disease and responses to treatment
can be observed between tumours with identical histological features, reflecting their high
molecular heterogeneity [3]. Furthermore, approximately 50% of cases develop metastasis
within 5 years, urging the identification of biomarkers to assist prognostication and the devel-
opment of more effective targeted therapeutics [4].
To meet this need, we have recently addressed the expression of the cancer-associated sia-
lyl-Tn antigen (STn) on a small prospective series of unselected bladder cancer patients [5].
STn is an abnormal post-translational modification that results from a premature stop in cell-
membrane proteins O-glycosylation by sialylation of the Tn antigen (Fig 1A). In bladder
tumours, STn it was mainly present in advanced stage cases, while absent from most low-grade
NMIBC [5]. Moreover, it was not expressed by the normal urothelium, denoting a cancer-spe-
cific nature [5]. Studies in vitro showed that STn expression endowed bladder cancer cells with
high invasion capability [5] and an immunotolerogenic phenotype, potentially favoring disease
dissemination [6]. Alterations in cell-surface protein glycosylation have be implicated in the
activation of intracellular oncogenic signalling pathways [7], including the phosphoinositide-3
kinase (PI3K)/Akt signalling pathway [8] which is thought to play a critical role in bladder can-
cer development. These preliminary observations support the hypothesis that STn expression
may play a key role in disease outcome, which warrants a deeper investigation. Several studies
also suggest that Tn antigen, which is a precursor of STn, may be also implicated in oncogenic
events [7]; however nothing is known about the expression of this glycan in bladder tumours.
The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin
(mTOR) pathways are interconnected signaling cascades essential for bladder cell growth and
survival (Fig 1B). The PI3K/Akt/mTOR or mTOR pathway integrates a multiplicity of extracel-
lular signals to regulate downstream signaling and protein synthesis, which ultimately leads to
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Fig 1. Schematic representation of membrane proteinO-glycosylation and the PI3K/Akt/mTOR pathways. A) Representation of membrane proteinO-
glycosylation with emphasis on the STn expression by cancer cells. This is a highly regulated process of critical importance for protein stability and function.
Briefly, newly synthesized proteins areO-glycosylated in the Golgi apparatus by the ppGalNAcTs-mediated addition of GalNAc moiety to Ser/Thr residues.
This originates the Tn antigen (GalNAc-O-Ser/Thr-protein backbone), which is the simplest O-glycan. In normal cells these chains are extended through the
sequential addition of other sugars first by CGALT-1 and then other enzymes. This culminates in highly complex, heterogeneous and elongated glycans
often terminated by ABO or Lewis blood group related antigens (left drawing). In cancer cells the Tn antigen is immediately sialylated by ST6GalNAc.I,
originating the STn antigen (Neu5Ac-GalNAc-O-Ser/Thr-protein backbone), thereby inhibiting further chain elongation (right drawing). The expression of STn
at the cell surface influences cell-cell adhesion and cancer cell recognition, favouring motility, invasion and immune escape. B) Schematic representation of
the PI3K/Akt/mTOR pathway, which is ubiquitously activated in bladder tumours. This is a highly conserved pathway regulated mainly by a wide variety of
extracellular signals, including mitogenic growth factors, hormones, nutrients, cellular energy levels, and stress conditions. These signals activate tyrosine
receptor kinases that recruit PI3K, which catalyses the conversion of membrane-bound PIP2 to PIP3. Then Akt and PDK-1 are activated through binding to
PIP3. PTEN preferentially dephosphorylates PIP3, inhibiting signalling progression. Full Akt activation requires double phosphorylation by PDK-1 itself and
PDK-2 (not shown). Akt phosphorylates mTOR directly or may also inactivate TSC1/TSC2 complex, inhibiting mTOR inactivation. mTORC1 triggers cell
growth and proliferation by phosphorylating eukaryotic translation regulators, among these p70S6 kinase (p70S6K or S6K1) that, in turn, phosphorylates the
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a competitive growth advantage, metastatic competence, angiogenesis, and therapy resistance
[9]. The signaling cascade begins with PI3K activation in the cell membrane followed by ser-
ine/threonine kinase Akt cell membrane translocation and activation. The best studied down-
stream substrate of Akt is the serine/threonine kinase mTOR, whose downstream effector is S6
kinase-1 (S6K1). In particular, a subset of mTOR pathway alterations have been shown to
occur in bladder cancer, such as mutations in PIK3CA gene, which culminates with increased
mTOR signaling and bladder cancer cells resistance to apoptosis [10]. Moreover, the pharma-
cological or biochemical inhibition of the PI3K pathway drastically reduced the invasive capac-
ity of bladder cancer cell lines. Furthermore, over half of primary human bladder tumours
present high Akt phosphorylation and the aberrant activation of this pathway has been sug-
gested to contribute to invasion [11]. Another event influencing mTOR pathway activation in
bladder tumours involves the loss of tumor suppressor PTEN (phosphatase and tensin homo-
log deleted on chromosome ten) function [12]. PTEN normally suppresses activation of the
PI3K/Akt/mTOR pathway antagonizing PI3K and preventing activation of Akt and PDK-1.
PTEN also functions to regulate chemotaxis and cell motility, thereby promoting tumor inva-
sion [13]. In summary, there are evidences that a comprehensive evaluation of PI3K/Akt/
mTOR pathway associated proteins may hold significant potential for value for patient stratifi-
cation. Moreover, many preclinical and clinical studies support that mTOR inhibitors, such as
sirolimus (rapamycin) and their derivatives may improve cancer treatment [13,14].
Based on these observations we hypothesize that Tn and/or STn may act synergistically with
the mTOR pathway to drive bladder cancer progression. As such, we have devoted to evaluat-
ing the expression of STn and proteins associated with the activation of the PI3K/Akt/mTOR
pathway activation in bladder tumours at different stages. We anticipate that the combination
of extracellular and intracellular oncogenic events may improve patient stratification and pro-
vide insights for novel therapeutics. Furthermore we have estimated the impact of sirolimus in
chemically-induced urothelial tumours in mice, envisaging the creation of a rationale for more
effective bladder cancer therapeutics.
Materials and Methods
Ethics Statement
This work involves experiences in tumour samples of patients diagnosed with bladder cancer
in the Portuguese Insitute of Oncology of Porto. All procedures were performed after patient’s
written informed consent and approved by the Ethics Committee of Portuguese Institute of
Oncology—Porto. All clinicopathological information was obtained from patients’ clinical
records.
It also involves animal experiments. All procedures involving animals were performed in
accordance with the European Directive 2010/63/EU. During the course of this study, the ani-
mals were fed ad libitum with standardized food (Tecklad Global Diet, Harlan, Spain). The fol-
lowing protocol was approved by the Portuguese Ethics Committee for Animal
Experimentation (Direção Geral de Veterinária, Approval no. 520/000/000/2003). All mice
used in the experiment were acclimatized for one week under routine laboratory conditions
before starting the experiments. They were housed randomly in groups of 4–5 in plastic cages,
with hard wood chips for bedding. The animals were maintained in a room with a controlled
ribosomal protein S6 (pS6), and the eukaryotic translation initiation factor 4E–binding protein 1 (4E-BP1). For the protein mTOR to activate its signalling
cascade, it must form the rapamycin-sensitive ternary complex mTORC1. Key PI3K/Akt/mTOR-pathway proteins pAkt, pmTOR and pS6 explored in this
studied are highlighted by orange circles.
doi:10.1371/journal.pone.0141253.g001
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temperature of 23±2°C, a 12-hour light/dark cycle and 55±5% humidity. The animals' drinking
solutions were changed once a week or earlier if necessary, and the volume drunk was recorded.
Weekly food intake was also noted. All mice were monitored throughout the experiment for
signs of distress and loss of body weight. The animals were sacrificed with 0.4% sodium pento-
barbital (1 ml/Kg, intraperitoneal).
Population
This study was performed in a retrospective series of 96 formalin-fixed paraffin-embedded
bladder tumours obtained from archived paraffin blocks at the Portuguese Institute of Oncol-
ogy—Porto (IPOP), Portugal. Bladder tumours were extracted from 82 men and 14 women,
ranging in age from 38 to 92 years (median of 69.5 years), admitted and treated at the IPOP
between 2005 and 2007. Forty seven of the examined tumours were histologically classified as
NMBIC (Ta and T1) and 49 as invasive lesions (T2-T4). Sixteen were low grade and 80 were
high grade tumours, according to the 2004 WHO grading criteria. Furthermore, carcinoma in
situ (CIS) was found concomitantly in 20.8% of the patients. The average follow up time period
was 45 months (1–134 months). Cystectomy was performed in 64 patients (66.7%) while the
other 32 (33.3%) were submitted to transurethral resection. Lymphadenectomy was performed
in approximately 47% of the patients and from those 37% presented metastasis. Fifty four
(56.3%) tumours were primary and 42 (43.7%) were recurrent tumors. From the recurrent
tumours, 38% had no prior treatment, 27% were treated with Mitomicin C, 11% with BCG and
19% were submitted to both treatments. Moreover 5% of these patients were treated with
neoadjuvant chemotherapy prior to the cystectomy. Table 1 summarizes the clinicopathologi-
cal information.
Cancer-specific survival (CSS) was defined as the period between the tumour removal by
surgery and either patient death by cancer or the last follow-up information. All procedures
were performed after patient’s informed consent and approved by the Ethics Committee of
IPO-Porto. All clinicopathological information was obtained from patients’ clinical records.
Immunohistochemistry
The expressions of STn antigen, its precursor Tn, and phosphorylated forms of Akt (pAkt),
mTOR (pmTOR), S6 (pS6) and PTEN in bladder tumours were accessed by immunohis-
tochemistry using the avidin/streptavidin peroxidase method, as described by Ferreira et al.
[5]. Information on the primary antibodies and dilutions used in this study are summarized in
Table 2. Immunoreactivity was revealed using diaminobenzidine (DAB, Thermo Scientific
LabVision) as chromogen and sections were counterstained with Harris’s hematoxylin. Nega-
tive controls were performed by replacing the primary antibody with 5% bovine serum albu-
min (BSA). Positive controls were known positive tissues for the antigens under study.
Immunohistochemistry scoring of human tumours
The immunostained sections were assessed double-blindly by light microscopy by two inde-
pendent observers (CC and SP) and validated by an experienced pathologist (TA). Disaccord-
ing readings were re-analyzed using a double-headed microscope (Olympus BX46; Olympus
Corporation), and consensus was reached. A semi-quantitative approach was established to
score the immunohistochemical labeling based on the extent and intensity of the staining.
Given the absence of Tn and STn in the healthy urothelium [5], tumours were classified as
positive for these antigens when membrane and/or cytoplasmic immunoreactivity were
observed in more than 5% of the tumour, as described by Ferreira et al. [5,15]. pAkt, pmTOR,
pS6 and PTEN expressions were scored according to the staining intensity (weak-1 point;
Glycosylation and PI3K/Akt/mTOR Pathway in Bladder Cancer
PLOS ONE | DOI:10.1371/journal.pone.0141253 November 16, 2015 5 / 19
moderate-2 points; strong-3 points) multiplied by the percentage of positive cells (0–5%-0
points;>5–25%-1 point;>25–50%-2 points;>50–75%-3 points;>75–100%-4 points). Based
on the classification proposed by Nishikawa et al. [16], tumours with a score<6 were consid-
ered negative, whereas those with a score6 were classified as positive (overexpression). pAkt
was evaluated based on nuclear immunoreactivity, pmTOR and pS6 based on cytoplasmic
expression and PTEN on both cytoplasmic and nuclear staining, as suggested by other publica-
tions [17,18].
Animal experiments with sirolimus and immunohistochemistry scoring
Histological sections of Imprinting Control Region (ICR) mice bearing N-butyl-N-(4-hydroxy-
butyl) nitrosamine (BBN)-induced bladder lesions, resulting from our previous work on the
impact of sirolimus on bladder cancer [19], were elected for this study. Briefly, four-week-old
male ICR mice (25g; Harlan, Barcelona, Spain) were randomly distributed into four groups, as
described in detail in a previous publication [18]. Group 1 (n = 6) included mice exposed to
0.05% BBN for 12 weeks followed by tap water for 8 weeks (total of 20 weeks). Group 2 (n = 7)
included mice treated with 0.05% BBN solution for twelve weeks, maintained with normal tap
water for another week, administrated intraperitoneally with mTOR-inhibitor sirolimus (1.5
mg/kg; Wyeth) for five days a week for six consecutively weeks, i.e. until the 19th week, followed
by another week of tap water (total of 20 weeks). Group 3 (n = 6) included mice exposed to
0.05% BBN for 12 weeks followed by tap water for 11 weeks (total of 23 weeks). Group 4
Table 1. Clinical-pathological data of the studied sample (n = 96).
Age, years
median [min—max] 69.5 [38–92]
Gender, n (%)
Male 82 (85.4%)
Female 14 (14.6%)
Stage, n (%)
Ta 27 (28.1%)
T1 20 (20.8%)
T2 9 (9.4%)
T3 20 (20.8%)
T4 20 (20.8%)
Grade, n (%)
Low 16 (16.7%)
High 80 (83.3%)
Recurrence status, n(%)
Primary 54 (56.3%)
Recurrent 42 (43.7%)
Associated Cis, n(%)
No 76 (79.2%)
Yes 20 (20.8%)
Metastasis, n(%)
No 19 (63.3%)
Yes 11 (36.7%)
Follow-up, n (%)
Alive, lost or death from other causes 67 (69.8%)
Death from cancer 29 (30.2%)
doi:10.1371/journal.pone.0141253.t001
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(n = 7) included mice treated with 0.05% BBN and sirolimus, as described for Group 2, but
with an exposure to tap water afterwards of 3 weeks (total of 23 weeks). Group 3 and 4 were
created to estimate the possibility of late relapse and/or molecular alterations resulting from
prolonged survival. All procedures were performed in accordance with the European Directive
2010/63/EU. During the course of this study, the animals were fed ad libitum with standardized
food (Tecklad Global Diet, Harlan, Spain). The histological changes induced by these experi-
ments included both preneoplastic and neoplastic lesions with invasive potential and invasive
tumours, as described in detail by Oliveira et al. [18]. Herein, lesions of high invasive potential
and muscle invasive tumours were screened for STn and pS6 by immunohistochemistry, as
described in detail for human tumours, since the antibodies used are reactive against both
human and mice. Both the intensity and the extension of immunostaining were taken into con-
sideration to score the expression of the antigens, as described in the previous section. The
bladder lesions and immunostaining were assessed double-blindly by two independent observ-
ers (CC and SP) and validated by an experienced veterinary pathologist (RMGC).
Statistical analysis
Statistical data analysis was performed with IBM Statistical Package for Social Sciences—SPSS
for Windows (version 20.0). Chi-square analysis was used to compare categorical variables.
Kaplan-Meier survival curves were used to evaluate correlation between STn expression and
cancer-specific survival (CSS) and were compared using log-rank test. Furthermore, multivari-
ate Cox regression analysis was performed to assess the individual effect of the evaluated mark-
ers on patient’s survival and adjust to potential confounders (variables that could affect CSS of
NMIBC and MIBC patients). The correlation between PI3K/Akt/mTOR pathway molecules
was performed using Spearman rho test.
Results
Altered protein glycosylation, translated by the expression of the STn antigen and its precursor
Tn, PI3K/Akt/mTOR pathway molecules (pAkt, pmTOR, pS6), and PTEN inactivation, are
salient features of bladder tumours. Herein we have devoted to a comprehensive analysis of
these molecular alterations in a series of bladder cancer patients at different stages of the dis-
ease, envisaging biomarkers of poor cancer-specific survival.
Our dataset was composed by 47 NMIBC and 49 MIBC patients, as showed in Table 1.
According to Fig 2, NMIBC presented a higher cancer-specific survival (CSS; mean CSS: 119
months) than MIBC patients (mean CSS: 43 months; log rank, p<0.001). These results
Table 2. Antibodies used in the immunohistochemical analysis.
Antibody Vendor Clone Dilution
Tn Non-commercial Hybridoma* IE3 1:5
STn Non-commercial Hybridoma* TKH2 1:20
Ki-67 Dako MIB-1 1:100
p53 Dako DO-7 1:100
Phos-AKT Cell Signaling Ser473 (736E11) 1:50
Phos-mTOR Cell Signaling Ser2448(49F9) 1:100
Phos-S6 Cell Signaling Ser240/244 polyclonal 1:75
PTEN Cell Signaling D4.3 XP 1:50
*Kindly provided by Prof. Celso Reis (IPATIMUP, UP, Portugal)
doi:10.1371/journal.pone.0141253.t002
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demonstrated that our series reflected the natural course of disease and highlighted the signifi-
cantly lower CSS of MIBC compared to NMIBC cases. Therefore, particular interest was set in
the identification of biomarkers for late stage disease based on the comparison between
NMIBC and MIBC.
Tn and STn antigen expressions in bladder cancer
The Tn antigen was observed in approximately 10% of NMBC and MIBC (Table 2) and its
expression was residual, did not exceeding 5% of the tumour area and without any defined pat-
tern. On the other hand, the STn antigen was detected in approximately 60% of the studied
bladder tumours, which is in accordance with our previous findings [5]. The antigen was pre-
dominately expressed at the cell membrane, although cytoplasmic staining could also be
observed. The STn antigen presented a focal expression that did not exceed 30% of the tumour
area for the majority of the positive cases, irrespectively of their histological origin. STn was
mainly expressed by dedifferentiated cells in tumours showing lamina propria (T1; 60%) and
muscularis propria ( T2; approximately 60–90%) invasion; conversely the percentage of posi-
tive Ta was lower than 30% (p<0.001; Fig 3A). Although without statistical significance, in Ta
tumours STn positive cells were mainly present in superficial tumour layers away from the ves-
sels. Conversely, STn positive cells in T1 tumours (Fig 3B) were observed accompanying and/
Fig 2. Association between disease groups and cancer-specific survival (CSS) in the studied patients.
Kaplan-Meier analysis showing the CSS of NMIBC (Ta and T1) and s of MIBC (T2,T3 and T4). Comparison
performed by log-rank test (p<0.001); + censored NMIBC patients; ^ censored MIBC patients.
doi:10.1371/journal.pone.0141253.g002
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or invading the basal layer (Fig 3B), while in MIBC these cells were mostly found in the inva-
sion fronts (Fig 3B) and invading and/or inside the vessels, which suggests a role in invasion
and disease dissemination. Reinforcing these observations, the presence of STn antigen was sta-
tistically higher in MIBC when compared to NMIBC (p = 0.001, Table 3).
PI3K/Akt/mTOR pathway in bladder cancer
The evaluation of the PI3K/Akt/mTOR/S6 pathway was done using antibodies for active phos-
phorylated forms of Akt (pAkt), mTOR (pmTOR), and S6 (pS6). PTEN, that negatively regu-
lates Akt signalling, was also evaluated.
pAkt was detected both in the cytoplasm and nucleus. In NMIBC cases several areas with
different intensity of expression were observed (Fig 4A), denoting a heterogeneous pattern that
was not evident in MIBC (Fig 4B). Furthermore, stromal cells of MIBC positive cases showed
enhanced staining intensity mainly in the areas close to the tumour. pmTOR immunoreactivity
Fig 3. STn expression in different bladder tumors stages. (A) Distribution of STn negative and positive tumors along the different stages of bladder
cancer; (B) Representative images of STn staining in NMIBC and MIBC. Left—NMIBC showing a predominance of STn positive cells in the superficial layers,
away from the fibrovascular support; note vessels without positive cells. Right—MIBC showing the invasion front with STn positively stained cells; note
positive STn urothelial cells in the vessels (arrow), suggesting possible involvement in metastasis.
doi:10.1371/journal.pone.0141253.g003
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was cytoplasmic and, in occasional cases, nuclear. In urothelium with apparent normal histol-
ogy pmTOR expression was restricted to superficial cell layers. In NMIBC pmTOR expression
was evenly distributed across the several layers of urothelial cells, although there was a more
intense staining in the superficial layers (Fig 4C). Moreover, several areas with variable staining
intensity were observed, denoting a heterogeneous expression. In MIBC positives cases,
pmTOR expression was focal and heterogeneous (Fig 4D). pS6 immunoreactivity was predom-
inantly cytoplasmic. In NMIBC pS6 expression was noted in all the superficial layers, both in
umbrella and differentiated cells (Fig 4E). The immunoreactivity of pS6 varied across the
tumour cells. In MIBC pS6 presented a diffuse expression throughout the tumour, being more
present in basal and mitotic cells (Fig 4F). Several positive cases presented increased pS6 stain-
ing intensity in the invasion front as well as pS6 expression in tumour infiltrating lymphocytes
and endothelial cells.
Taking into account the extension of staining and its intensity, 62/94 (66%), 33/96 (34%)
and 45/95 (47%) of the bladder tumours were considered positive for pAkt, pmTOR and pS6,
respectively. A Spearman rho test showed that pAkt, pmTOR, pS6 expressions were signifi-
cantly correlated (P<0.05) irrespectively of the tumour stage, thus in accordance with a fully
active pathway. Furthermore, despite histological differences, these markers presented an equal
distribution among the NMIBC and MIBC and could not be associated with muscle invasion
(Table 3).
On the other hand, 37/92 (40%) of the tumours were considered positive for PTEN. PTEN
was expressed in the cytoplasm and nucleus of the same cells, however with lower extension of
expression in MIBC (33%, Fig 4G) compared to NMIBC (83%; Fig 4H). Moreover, the PTEN-
negative phenotype was significantly associated with muscle invasion (Ta and T1; p<0.001,
Table 3), which may contribute to maintain an active PI3K/Akt/mTOR/S6 pathway in these
cases.
Table 3. Association between the evaluatedmarkers and the stage of disease.
Bladder Cancer
NMIBC MIBC P
n (%) n (%)
Tn
Negative 41 (87.2) 45 (91.8)
Positive 6 (12.8) 4 (8.2) 0.461
STn
Negative 27 (57.4) 12 (24.5)
Positive 20 (42.6) 37 (75.5) 0.001
pAKT
Negative 13 (28.9) 19 (38.8)
Positive 32 (71.1) 30 (61.2) 0.312
pmTor
Negative 30 (63.8) 33 (67.3)
Positive 17 (36.2) 16 (32.7) 0.717
pS6
Negative 22 (47.8) 28 (57.1)
Positive 24 (52.2) 21 (42.9) 0.183
PTEN
Negative 18 (38.3) 37 (82.2)
Positive 29 (61.7) 8 (17.8) <0.001
doi:10.1371/journal.pone.0141253.t003
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Fig 4. Expressions of pAkt, pmTOR, pS6 and PTEN in NMIBC and MIBC (40xmagnification). A and B)
pAKT nuclear and cytoplasmatic expression in NMIBC (A) and MIBC (B). In NMIBC cases pAkt presented a
heterogeneous pattern with areas of different intensity of expression. In MIBC, stromal cells mainly in the
areas close to the tumour showed higher expression. C and D) pmTOR cytoplasmic expression in NMIBC (C)
and MIBC (D). In NMIBC pmTORwas expressed across several layers, although there was a more intense
staining in the superficial ones. In MIBC positive cases pmTOR expression was focal. E and F) pS6
cytoplasmatic expression in NMIBC (E) and MIBC (F). In NMIBC pS6 expression was observed in all the
superficial layers both in umbrella and differentiated cells. In MIBC the immunoreactivity was diffuse, however
more present in basal and mitotic cells. pS6 expression was higher in the invasion front and in tumour
infiltrating lymphocytes and endothelial cells. G and H) PTEN cytoplasmic and nuclear expressions in NMIBC
(G) and MIBC (H). PTEN expression was higher in NMIBC compared to MIBC.
doi:10.1371/journal.pone.0141253.g004
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Tn, STn, PI3K/Akt/mTOR pathway and Cancer-specific Survival
A Kaplan-Meier analysis was used to evaluate associations between the addressed biomarkers
and the cancer-specific survival of patients. We observed that patients bearing STn expressing
tumours had a lower CSS, irrespectively of their stage (p = 0.024; Fig 5A). This was also
observed when evaluating NMIBC alone (p = 0.020; Fig 5B). More importantly, among
NMIBC, STn expressing T1 tumours presented lower CSS than negative tumours (p<0.05).
Moreover, multivariate Cox regression analysis adjusted to potential confounders, namely age,
gender, stage, grade, recurrence status, presence of concomitant CIS was performed. We found
that STn is an independent prognostic marker of worst CSS (HR = 11.836; 95%CI: [1.063–
131.7]; p = 0.044). Contrasting with STn, positive Tn, pAkt, pmTOR and pS6 tumours showed
no differences in CSS compared to negative lesions, irrespectively of their stage. We have also
observed that patients harbouring PTEN-negative tumours had lower CSS (p = 0.015, Fig 6).
More studies are necessary to determine if the lack of suppressive effect of PTEN over PI3K/
Akt/mTOR may account for these findings.
Based on these observations and aiming to improve the prognostic value of STn in the con-
text of late stage disease (MIBC), we have comprehensively integrated the information from
STn and PI3K/Akt/mTOR pathway biomarkers. According to Fig 7, the introduction of PI3K/
Akt/mTOR pathway molecules allowed discriminating STn positive MIBC tumours with worst
CSS (p = 0.027). Furthermore, multivariate Cox regression analysis (adjusted to age, stage,
recurrence status, presence of concomitant CIS and metastasis) revealed that the presence of
PI3K/Akt/mTOR pathway molecules in STn+ MIBC is independently associated with approxi-
mately 6-fold risk of death by cancer (HR = 5.662; 95%CI: [1.093–29.323]; p = 0.039). These
observations suggest, for the first time, that the combination of STn and mTOR pathway bio-
markers may hold potential to improve the stratification of advanced stage bladder tumours;
however corroboration in larger series is mandatory.
Inhibition of the PI3K/Akt/mTOR pathway in animal models
BBN-induced mice bladder tumours mimicking the histology and molecular nature of human
cancers [20,21], were screened for STn and pS6, the downstream effector of mTOR pathway.
We observed no STn expression in the healthy mice urothelium, in accordance with previous
observation for the healthy human bladder [5]. In mice healthy urothelium pS6 expression was
below 20%, thus underexpressed when compared with BBN-exposed mice (Fig 8). In the con-
trol groups (Group 1 and 3, Fig 8A), the exposure to BBN led to the development of invasive
tumours in 70–90% of the studied mice. Concomitantly, 83–100% of the invasive lesions over-
expressed the STn antigen and all significantly overexpressed pS6 (Fig 8B). This demonstrated
that BBN-induced lesions were able to recapitulate the association between altered glycosyla-
tion and an activated PI3K/Akt/mTOR pathway previously observed in advanced stage human
tumours. The STn antigen was mainly found in cells adjacent to the basal layer and in those
invading the stroma, as previously observed in human tumours (Fig 8B and 8C). Conversely,
pS6 presented a more diffuse expression, again in accordance with the pattern observed in
human lesions (Fig 8B and 8C). A comparison between groups 1 and 3 further highlighted that
extended lifespan did not alter the number of invasive lesions, but significantly increased STn
and pS6 overall expressions in each tumour (p<0.05; Fig 8B), highlighting the more aggressive
nature of Group 3 lesions.
In the sirolimus-treated groups (Groups 2 and 4; Fig 8A) a smaller number of mice devel-
oped invasive tumors (20–40%) when compared to the controls (Groups 1 and 3). Moreover,
only 43% of the mice treated with sirolimus overexpressed the STn antigen, irrespectively of
the experience periods. Still, the extension of STn expression was significantly decreased in
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STn-positive tumours when compared to the control groups (Fig 8B and 8C). Following the
same tendency, the pS6 protein was only overexpressed in 29% of the cases in Group 2 and the
extension of expression was also significantly decreased (Fig 8B and 8C). Contrastingly, the
expression of pS6 in Group 4 was higher than in Group 2, again translating the higher aggres-
sive nature of tumours obtained after longer lifespan. Despite these observations, sirolimus
treatment promoted a significant reduction in the percentage of positive pS6 cells in Group 4
mice when compared to Group 3 (p<0.05; Fig 8B and 8C). Altogether, sirolimus administra-
tion effectively reduced tumour burden and promoted a significant reduction in the expression
of STn and pS6 markers.
Discussion
Due to their high molecular heterogeneity, advanced stage bladder tumours present a signifi-
cant prognostication and treatment hurdle. In this context, much controversy exists regarding
the potential of conventional cancer biomarkers, urging the identification of novel molecules
capable of aiding disease personalization. Furthermore, advanced stage bladder cancer remains
an orphan disease in terms of therapeutics, as the only available options continue to be surgery
and conventional chemotherapy [22]. The introduction of targeted therapeutics is therefore
warranted.
In a previous explorative study we have observed that altered protein glycosylation trans-
lated by STn overexpression was a salient feature of a subset of advanced stage tumours [5].
Herein we have started by investigating the expression of STn precursor, the Tn antigen, in
bladder tumours. We observed that this antigen presented a very low expression in bladder
Fig 5. Effect of STn expression in cancer-specific survival (CSS). Kaplan–Meier analysis showing the association between STn and CSS in: (A) all
studied bladder cancer patients; (B) NMIBC patients. Comparison performed by log-rank test (A: p = 0.024; B: p = 0.020); + censored STn negative tumours;
^ censored STn positive tumours.
doi:10.1371/journal.pone.0141253.g005
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tumours and was not associated with any particular stage of the disease. These findings suggest
that the Tn antigen is rapidly sialylated or capped with more extended glycans in bladder
tumours. Moreover, we have confirmed that STn expression is more associated with muscle
invasive than non-muscle invasive disease in a larger patient set, suggesting that sialylation
plays a key role in stopping protein glycosylation in advanced stage bladder tumours. Further-
more, we have provided new insights regarding its correlation with decreased survival, as previ-
ously observed for digestive track tumours [23–25]. Accordingly, we and other authors have
shown that STn expression is responsible by the modulation of cell surface glycoprotein func-
tions in ways that favour malignant phenotypes in gastric [26], breast [27] and bladder [5] can-
cers. Namely, STn expression altered the adhesive properties of cancer cells, possibly by
impairing integrin function [26,27]. Furthermore, it enhanced cell motility, invasion [26,27]
and epithelial-to-mesenchymal transition, a key event leading to metastasis [28]. We have also
demonstrated that STn expression protects bladder cancer cells from adverse host immune
responses [6]. Namely, it impaired dendritic cell maturation inducing a tolerogenic phenotype
and limiting their capacity to trigger protective anti-tumour T-cell responses [6]. In resume, a
significant amount of data supports a key role of STn in disease progression and dissemination,
making of STn antigen, and in particular STn-glycoproteins, potential anti-cancer targets. Nev-
ertheless, there is scarce information about the molecular nature of this subset of STn-express-
ing aggressive tumours and consequently about the best therapeutic options.
Fig 6. Effect of PTEN expression and cancer-specific survival (CSS) in the studied patients. Kaplan-
Meier analysis showing the effect in CSS of PTEN expression in all studied bladder cancer patients.
Comparison performed by log-rank test (p = 0.013); + censored PTEN negative tumours; ^ censored PTEN
positive tumours.
doi:10.1371/journal.pone.0141253.g006
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Foreseeing a more accurate patient stratification we have also addressed the expression of
PI3K/Akt/mTOR pathway markers in bladder tumours. In our series the activation of mTOR
pathway proteins did not discriminate the stage of disease. Moreover it did not allow, by itself,
the identification of patients facing worst prognosis, which is in accordance with recent publica-
tions [29,30]. However, we found that PTEN expression, which exerts a suppressive effect over
the PI3K/Akt/mTOR pathway, was decreased in advanced stage tumours, in accordance with
previous observations [31–34]. Furthermore, PTEN-negative MIBC presented worst cancer-spe-
cific survival in comparison to PTEN-positive lesions. More studies are needed to determine if
the lack of suppressive effect over the PI3K/Akt/mTORmay account for poorer outcome. Inter-
estingly, we have also observed that the overexpression of PI3K/Akt/mTOR pathway biomarkers
decisively associated with worst CSS in STn positive advanced stage tumours, which currently
lack effective therapeutics. These findings lead us to hypothesize that this subset of more aggres-
sive bladder tumours may benefit frommulti-targeted approaches combining mTOR-inhibitors
and guided therapeutics against STn-expressing cells. However these are preliminary insights
from a relatively low number of patients. More studies involving a large population are war-
ranted to confirm these observations. It will also be important to evaluate other outcomes of
aggressiveness, namely response to conventional therapeutics and metastasis development.
Our study also reinforced that bladder tumours present extensive activation of the PI3K/Akt/
mTOR pathway irrespectively of their histological nature, as described in previous publications
[32,35]. Such findings contribute to support the idea that most bladder tumours may be good
candidates for mTOR-inhibitors therapeutics. Accordingly, mTOR-inhibitors have been
Fig 7. Effect of PI3K/Akt/mTOR pathway activation in cancer-specific survival (CSS) of patients with
STn positive MIBC. Kaplan–Meier analysis showing the association between pAKT, pmTOR and pS6
expressions in the CSS of STn positive tumors MIBC: Comparison performed by log-rank test (p = 0.027);
+ censored pAKT and pmTOR and pS6 negative tumours; ^ censored pAKT and/or pmTOR and/or pS6
positive tumours.
doi:10.1371/journal.pone.0141253.g007
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extensively explored in pre-clinical settings and two phase I/II clinical trials for bladder cancer
are ongoing [36]. In particular our group has demonstrated that the combination of everolimus
with cisplatin or gemcitabine decreased the proliferation of bladder cancer cell lines in compari-
son to the chemotherapy agent alone [14,37]. More recently we conducted studies in mice bear-
ing chemically-induced tumours mimicking the histological and molecular nature of human
tumours [20]. We concluded that administration of mTOR-pathway inhibitor sirolimus (rapa-
mycin) effectively reduced the frequency of invasive lesions. Using the same animal model, we
have now confirmed the anti-cancer activity of sirolimus in the context of aggressive bladder
disease. Namely, we observed a significant reduction in tumour burden accompanied by a loss
of pS6 expression, thus in accordance with the expected mechanism of action of the drug. More-
over, we are describing for the first time that chemically-induced bladder tumours expressed the
Fig 8. STn and pS6 expressions in bladder tumours from BBN-exposedmale ICRmice with or without the administration of mTOR-inhibitor
sirolimus (rapamycin). A) Experimental design to determine the sirolimus effect on STn and pS6 expressions in a model of urothelial carcinogenesis (male
ICRmice). B) Expression of STn and pS6 in BBN-derived urothelial tumours in the presence and absence of sirolimus. BBN-induced bladder tumours
(Groups 1 and 3) overexpressed STn and pS6, which was more pronounced in Group 3, after longer lifespan. Exposure to sirolimus decreased the number of
invasive lesions in groups 2 and 4 (data not shown) and, concomitantly, decreased the expressions of STn and pS6. C) Histological sections showing the
expressions of STn and pS6 in BBN-induced urothelial tumours before and after treatment.
doi:10.1371/journal.pone.0141253.g008
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STn antigen, thereby mimicking the glycosylation pattern of human cancers. These observations
are of particular importance due the lack of accurate models to access the biological role of this
antigen. In fact most established cancer cell lines express residual amounts of this antigen,
denoting a dependence on the tumours microenvironment. We believe that BBN-induced
tumours may now constitute key models to develop successful therapeutics against STn positive
bladder lesions. Moreover importantly, we have concluded that the administration of sirolimus
contributed to reduce the number of STn positive cells. These observations reinforce a possible
association between STn and an active PI3K/Akt/mTOR pathway in invasive tumours, as sug-
gested upon the evaluation of human cancers. It also points out that sirolimus may constitute a
valuable approach to manage STn and PI3K/Akt/mTOR-positive, which face worst OS. Still,
these preliminary evidences and more in depth studies are needed before progressing to clinical
phases. Namely, it will be important to support these findings in other models such as patient-
derived xenografts and compare the effect of sirolimus with conventional chemotherapeutics
for bladder cancer (cisplatin/gemcitabine-based regimens).
In resume, we have demonstrated that the STn antigen is a biomarker of poor prognosis,
particularly in MIBC. We also suggest the existence of potentially more aggressive subgroup of
STn positive MIBC characterized by an active mTOR-pathway. Such observations also provide
the first link between these two apparently unrelated events in bladder cancer (altered glycosyl-
ation and the PI3K/Akt/mTOR-pathway activation). Using animal models we have also con-
cluded that the administration of mTOR-pathway inhibitor sirolimus offers potential against
these highly malignant tumours. More validation studies are now warranted to set the pace for
clinical trials. Taking into consideration its cell-surface nature and key role played by STn
malignancy, specific antibody-based therapeutics can also be envisaged [22,38]. The combina-
tion of these approaches may provide novel ways to improve MIBC management, which
remains an orphan disease in terms of innovative treatments [22].
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